Details of the Drug

General Information of Drug (ID: DM13OVF)

Drug Name
REMD 477
Synonyms Volagidemab
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 2 [1]
Type 2 diabetes 5A11 Phase 1/2 [2]
Type-2 diabetes 5A11 Phase 1/2 [3]
Drug Type
Antibody
Cross-matching ID
TTD ID
DLV0Z8
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Antagonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03117998) Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
4 Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.